In Short Order, Merck And Stallergenes File BLAs For New Allergy Immunotherapies
This article was originally published in The Pink Sheet Daily
Both Merck and French biotech Stallergenes have filed BLAs with FDA for approval of their respective grass allergy immunotherapies.
You may also be interested in...
Vaccine and immunotherapy-focused Selecta, up to now focused on grants for funding, signs its first big pharma partner around targeted, antigen-specific programs for undisclosed allergies.
U.K. biotech Circassia has the first potential cat allergy vaccine to reach advanced clinical studies in Europe and the U.S., funded by a large round of VC financing completed in 2011. Its allergen-free technology could revolutionize the treatment of allergies.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.